The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2018;11(1): 22‑26

Read: 50176 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2018;11(1):22‑26. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Roddy E., Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12: 223—234.
  2. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894—900.
  3. Krishnan E., Svendsen K., Neaton J.D., et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168: 1104—1110.
  4. FDA announces new recommenda- tions on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes. Pharmaceutical Online. December 18, 2008 (https://www.pharmaceuticalonline.com/ doc/fda-announces-new-recommendations-on-0001).
  5. Schumacher H.R. Jr, Becker M.A., Wortmann R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540—1548.
  6. Becker M.A., Schumacher H.R. Jr, Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.
  7. Schumacher H.R. Jr, Becker M.A., Lloyd E., et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188—194.
  8. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895—900.
  9. Khanna D., Khanna P.P., Fitzgerald J.D., et al. 2012 American College of Rheuma- tology guidelines for the management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;63:1447—1461.
  10. White W.B., Chohan S., Dabholkar A., et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidi- ties. Am Heart J 2012;164:14—20.
  11. Foody J., Turpin R.S., Tidwell B.A., et al. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits 2017;10:393—401.
  12. Singh J.A., Ramachandaran R., Yu S., Curtis J.R. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord 2017;17:76.
  13. Wei L., Mackenzie I.S., Chen Y., et al. Impact of allopuri- nol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011;71:600—607.
  14. Bardin T., Keenan R.T., Khanna P.P., et al. Lesinurad in combination with allopu- rinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017;76:811—820.
  15. Grewal H.K., Martinez J.R., Espinoza L.R. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 2014;10:747—758.
  16. Sanchez-Lozada L.G., Tapia E., Bautista-García P., et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008;294:F710—718.
  17. Zhao L., Roche B.M., Wessale J.L., et al. Chronic xanthine oxidase inhibition fol- lowing myocardial infarction in rabbits: effects of early versus delayed treatment. Life Sci 2008;82:495—502.
  18. Xu X., Hu X., Lu Z., et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008;14:746—753.
  19. Hou M., Hu Q., Chen Y., et al. Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure. J Cardiovasc Pharmacol 2006;48:255-63.
  20. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010;49:1229—1238.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.